Cypherpunk Technologies Appoints Zcash CEO as Strategic Advisor to Enhance Privacy Tech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: PRnewswire
- Strategic Advisor Appointment: Cypherpunk Technologies has appointed Josh Swihart, CEO of Electric Coin Company, as a Strategic Advisor, leveraging his leadership experience in the Zcash ecosystem to drive the development of privacy-enhancing technologies, thereby strengthening the company's competitive edge in the digital asset space.
- Rebranding and Strategy: Following a $58.88 million private placement, Cypherpunk rebranded from Leap Therapeutics to Cypherpunk Technologies and launched a Zcash-focused digital asset treasury strategy, demonstrating its firm commitment to the privacy technology market.
- Asset Acquisition Plan: As of November 17, 2025, Cypherpunk has invested approximately $68 million to acquire 233,644.56 ZEC, representing about 1.43% of the total Zcash network supply, which will enhance its market position in privacy digital infrastructure.
- Leadership Expansion: With the addition of Zcash founder Zooko Wilcox, Cypherpunk's leadership team is expanding, indicating that the company's innovation and execution capabilities in the privacy technology sector are accelerating, aiming to create long-term value for shareholders.
Analyst Views on CYPH
About CYPH
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
